News

ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a no objection letter (NOL) from Health Canada to an Amendment of the Company’s Phase 1 clinical trial of RLS-0071 in healthy volunteers. The study design has been modified to add three multiple ascending dose (MAD) cohorts and an additional single ascending high dose (SAD) cohort to the trial.

“The revised trial design amendment will enable us to expeditiously execute the SAD and MAD parts of this Phase 1 clinical trial and obtain important PK-PD, safety and tolerability data that will inform future Phase 2 clinical trial protocols addressing our target indications,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “We look forward to providing additional updates on the trial and obtaining data from this study as it progresses and continues to support our other programs.”

Prior to the amendment, the Phase 1 trial was a single ascending dose randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK and PD of RLS-0071 in healthy subjects.

Recent News

05/28/2021

Study Upgrades of the Largest Databases of Neuronal Types

A study led by researchers from the Institute Cajal of Spanish Research Council (CSIC) in Madrid, Spain in collaboration with the Bioengineering Department of George Mason University in Virginia, U.S. has updated one of the world’s largest databases on neuronal types, Hippocampome.org. The study, which is published in the journal PLOS Biology, represents the most

05/26/2021

Southern Spine Announces John E. Hart as President and Chief Executive Officer

Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced that John E Hart has been named as President and Chief Executive Officer to lead the company. Hart has more than 35 years of executive leadership experience in the medical device, life science and biologics fields serving in general

05/25/2021

CIT Announces Key Additions to GAP Funds Investment Team

The Center for Innovative Technology (CIT), the nonprofit operations arm of the Virginia Innovation Partnership Authority (VIPA), announced that CIT GAP Funds has added two new Investment Associates to its team: Dustin Dunbar and Anthony Obi Jr. As Investment Associates, Dunbar, and Obi will support CIT GAP Funds activity including deal sourcing and due diligence